Compounding news

Enforcement Report - Right Value Drug Stores

Form 483 - Houston RX

Houston Pharmacy Behind Recalled Compounded Tirzepatide Vials Drew 14 FDA Inspection Observations, Including Exposed Skin and Research-Grade Ingredients

Apothecary Pharma

Enforcement Report: Tizepatide recall, Apothecary Pharma

SA health regulators crack down on compounded weight-loss drugs as pharmacy rules tighten

Black mold, bugs found at Chinese plants making GLP-1 compounding agents

Enforcement Report - Carolina Infusion, Inc

Compounding Pharmacies for Weight-Loss Drugs Are Booming. Should You Trust Them?

Policymakers Must Take Action to Preserve the Purpose of Medication Compounding and the Integrity of the Medicine Supply Chain

Greenwich Rx Issues Voluntary Nationwide Recall of Compounded Glutathione Due to Elevated Endotoxin Levels

FDA Warns Pharmacy About Illegal GLP-1 Compounding

Exclusive—Dr. Michael C. Burgess: We Need a New Playbook to Guard Against Counterfeit Drug Ingredients from China

RX Border Defense

Novo Nordisk secures injunction over Ozempic, Wegovy claims

Centric Compounding Issues Nationwide Recall of Glutathione, Myer’s Cocktail, and Tri-Immune Boost Due to Elevated Endotoxin Levels

Compounded Semaglutide and Tirzepatide Have Drawn More Than 1,700 Federal Problem Reports as Peptide Sales Climb

$elling $kinny: How a weight-loss startup kept shipping risky diet drugs while patients landed in the hospital

Fewer Than One in Four New Compounding Facilities Were Inspected, and Every Inspected Site Had Violations

Surge in unapproved GLP-1 drugs alarming poison control, safe medicine advocates

The peptide surge has reached compounding - Australian Pharmacist

FDA reminds compounders not to use dietary supplement grade glutathion

A Second Texas Pharmacy Recalls Compounded Glutathione Injections Across Fourteen States Over Elevated Bacterial Toxin Levels

A quantitative and qualitative study of US FDA inspection reports of 503B outsourcing facilities

Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. - 731761 - 08/06/2026

Navigating Compounding Peptides and GLP-1s Through Regulations | Drug Topics

Statement from Partnership for Safe Medicines on new litigation alleging illegal distribution of retatrutide

One Year Later: What the Compounding Industry Taught Us About Regulatory Compliance

Lilly sues six companies over alleged illegal sales of experimental obesity drug retatrutide

GLP-1 Solution - 715883 - 09/09/2025 | FDA